- 米国企業
- INOVIO PHARMACEUTICALS, INC.
INOVIO PHARMACEUTICALS, INC.INO
時価総額
$32.8億
PER
| 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | |
| Revenue from Contract with Customer, Excluding Assessed Tax | 10 | 4 | 13 | 10 | 41 | 35 | 42 | 30 | 4 | 7 | 2 | 10 |
| Research and development | 20 | 18 | 21 | 34 | 58 | 89 | 99 | 95 | 88 | 94 | 249 | 188 |
| General and administrative | 12 | 11 | 14 | 16 | 18 | 24 | 28 | 29 | 27 | 37 | 54 | 90 |
| Total operating expenses | 31 | 28 | 33 | 50 | 75 | 112 | 126 | 125 | 115 | 131 | 303 | 278 |
| Loss from operations | -21,638,540 | -23,493,532 | -19,544,332 | -39,495,961 | -34,283,702 | -76,235,937 | -83,642,901 | -94,091,138 | -111,108,545 | -124,082,044 | -301,217,919 | -267,573,520 |
| Interest income | - | - | - | - | - | - | - | - | 3 | 3 | 3 | 5 |
| 6.50% Convertible Senior Notes Due 2024 | - | - | - | - | - | - | - | - | 7 | 7 | 2 | 1 |
| Interest expense | - | - | - | - | - | - | - | - | 8 | 9 | 2 | 1 |
| Change in fair value of derivative liability | - | - | - | - | - | - | - | - | -1,763,652 | -75,670,977 | - | - |
| (Loss) gain on investment in affiliated entities | -2,390,498 | 2 | -1,038,745 | 3 | 3 | 1 | -6,982,664 | -1,988,567 | -3,090,557 | 37 | -553,570 | -1,899,654 |
| Equity Securities, FV-NI, Unrealized Gain (Loss) | - | - | - | - | - | - | - | - | - | 2 | -3 | -8 |
| Other (expense) income, net | - | - | - | - | - | - | - | - | 496,200 | -704,896 | 343,371 | -3,861,584 |
| Gain on deconsolidation of Geneos | - | - | - | - | - | - | - | - | - | 4 | - | - |
| Convertible Bonds | - | - | - | - | - | - | - | - | - | -8,177,043 | - | - |
| 6.50% Convertible Senior Notes Due 2024 | - | - | - | - | - | - | - | - | - | 9 | - | - |
| Net loss before share in net loss of Geneos | - | - | - | - | - | - | - | - | - | - | - | -277,652,852 |
| Share in net loss of Geneos | - | - | - | - | - | - | - | - | - | -4,584,610 | -434,387 | -2,165,213 |
| Net loss | -15,304,095 | -19,712,980 | -66,083,532 | -36,140,133 | -29,102,837 | -73,740,339 | -88,205,772 | -96,967,830 | -120,551,777 | -167,474,914 | -303,658,710 | -279,818,065 |
| Net loss attributable to non-controlling interest | -51,150 | -44,025 | -55,084 | -18,420 | 84,769 | - | - | - | -1,192,558 | -1,063,757 | - | - |
| Net loss attributable to Inovio Pharmaceuticals, Inc. | -15,252,945 | -19,668,955 | -66,028,448 | -36,121,713 | -29,102,837 | -73,740,339 | -88,205,772 | -96,967,830 | -119,359,219 | -166,400,000 | -303,658,710 | -279,800,000 |
| Earnings Per Share, Basic | - | - | - | -0.61 | -0.43 | -1.01 | -1.08 | -1.05 | -1.21 | - | -1.45 | -1.17 |
| Earnings Per Share, Diluted | - | - | - | -0.64 | -0.44 | -1.01 | -1.09 | -1.05 | -1.21 | - | -1.45 | -1.17 |